Verve Therapeutics (VERV) Expected to Announce Quarterly Earnings on Wednesday

Verve Therapeutics (NASDAQ:VERV - Get Free Report) is anticipated to release its Q1 2025 earnings data before the market opens on Wednesday, May 14th. Analysts expect the company to announce earnings of ($0.71) per share for the quarter.

Verve Therapeutics (NASDAQ:VERV - Get Free Report) last announced its earnings results on Thursday, February 27th. The company reported ($0.58) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.72) by $0.14. The business had revenue of $13.08 million during the quarter, compared to analysts' expectations of $3.94 million. Verve Therapeutics had a negative net margin of 807.65% and a negative return on equity of 35.23%. On average, analysts expect Verve Therapeutics to post $-2 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Verve Therapeutics Stock Down 15.5 %

NASDAQ:VERV opened at $4.36 on Wednesday. The firm has a market cap of $388.66 million, a PE ratio of -1.77 and a beta of 1.82. Verve Therapeutics has a 12 month low of $2.86 and a 12 month high of $9.31. The company's 50-day moving average price is $5.10 and its two-hundred day moving average price is $5.94.

Analyst Ratings Changes

A number of equities research analysts recently commented on the company. Canaccord Genuity Group increased their price target on Verve Therapeutics from $32.00 to $39.00 and gave the stock a "buy" rating in a research report on Tuesday, April 15th. Guggenheim upped their price objective on Verve Therapeutics from $18.00 to $24.00 and gave the company a "buy" rating in a report on Tuesday, April 15th. HC Wainwright lifted their price target on shares of Verve Therapeutics from $15.00 to $25.00 and gave the stock a "buy" rating in a research report on Monday, April 14th. Cantor Fitzgerald upgraded shares of Verve Therapeutics from a "neutral" rating to an "overweight" rating in a report on Tuesday, April 15th. Finally, William Blair reiterated an "outperform" rating on shares of Verve Therapeutics in a report on Friday, February 21st. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat, Verve Therapeutics presently has an average rating of "Buy" and an average price target of $25.75.

About Verve Therapeutics

Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.